Results 271 to 280 of about 740,817 (321)

Evolution of Prime Editing: Enhancing Efficiency and Expanding Capacity

Advanced Science, EarlyView.
Most rare diseases are caused by genetic mutations. Prime editing (PE) has emerged as a versatile tool capable of inducing diverse mutations without generating DNA double‐strand breaks. Despite its significant clinical potential, PE faces limitations in terms of efficiency and scalability.
Jihyeon Yu, Ju‐Chan Park, Heesoo Uhm, Yong‐Woo Kim, Hyeon Woo Im, Sangsu Bae   +5 more
wiley   +1 more source

Characterization of p53 p.T253I as a pathogenic mutation underlying Li-Fraumeni Syndrome. [PDF]

PLoS One
Holcomb NC, Harrington AM, Pu H, Halilovic B, Shelman NR, Zhang S, Sears C, Armstrong T, Shelton B, Corum L, D'Orazio JA.   +10 more
europepmc   +1 more source

Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer

Advanced Science, EarlyView.
This study establishes dual‐aptamer PROTACs targeting SETDB1 using a SETDB1‐specific aptamer conjugated to AS1411. The designed PROTACs penetrate cells, recruit MDM2 to degrade SETDB1, and inhibit cancer cell proliferation and migration. Remarkably, they also overcome tamoxifen resistance and enhance CD8+ T cell cytotoxicity, suppressing tumor growth ...
Yanxuan Guo, Yingge Lv, Shuyu Huang, Chang Liu, Yan Ouyang, Bei Lan, Chenghao Xuan   +6 more
wiley   +1 more source

The Ku80-p53-SIRT1 axis in DNA damage response contributes to sporadic and familial ALS and FTD. [PDF]

Nat Commun
Jun YW, Lee S, Almeida S, Freude KK, Ichida JK, Gao FB.   +5 more
europepmc   +1 more source

Prognostic significance of ER, PR and P53 mutation by histological type in postmenopausal early-stage endometrial cancer

Yong Ji, Ji Soo Lee
openalex   +1 more source

Mapping CSC‐Mediated Ovarian Cancer Chemoresistance via CXCR4‐PET to Guide Precision Cisplatin Re‐Sensitization Therapy

Advanced Science, EarlyView.
CXCR4 functions as a potential cancer stem cell‐associated marker linked to chemoresistance in ovarian cancer, and an inhibitor of CXCR4, AMD3100, can enhance the cytotoxic response to cisplatin. Based on these findings, [68Ga]Ga‐Pentixafor positron emission tomography enables selective visualization of CXCR4‐high ovarian cancer, while AMD3100 combined
Lixia Feng, Simei Zhao, Zheng Wei, Wenwen Wang, Feiquan Ying, Lin Huang, Mengna Zhu, Mengqing Chen, Qiang Yang, Si Sun, Dawei Jiang, Lingling Gao, Jing Cai   +12 more
wiley   +1 more source

Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells. [PDF]

Breast Cancer Res Treat
Tahaney WM, Lanier A, Qian J, Moyer CL, Nguyen N, Ma Y, Hill J, Powell RT, Stephan CC, Davies PJA, Mazumdar A, Brown PH.   +11 more
europepmc   +1 more source

EDTA‐Functionalized Nanoscale Metal–Organic Framework for Onco‐Cardiology via Radiochemotherapy Synergy and Spatiotemporally Matched Iron Chelation

Advanced Science, EarlyView.
Doxorubicin (DOX)‐induced cardiotoxicity is a major limitation to its broader clinical application, while cardioprotective interventions often risk reducing the anticancer efficacy of DOX. To address these challenges, this work constructs an EDTA‐functionalized metal–organic framework that enhances tumor therapy and provides efficient cardioprotection ...
Daojing Yuan, Liyang Tian, Luwen Zhuang, Yongyu Liang, Lingfei Chen, Xuetao Wang, Yanli Li, Xiyong Yu, Teng Gong   +8 more
wiley   +1 more source

Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer. [PDF]

J Clin Med
Harsanyi S, Novakova ZV, Neuschlova L, Galbavy S, Danisovic L, Ziaran S, Bevizova K.   +6 more
europepmc   +1 more source